News Read the latest news from Astellas Gene Therapies Jan 15, 2020 Astellas Completes Acquisition of Audentes Therapeutics Read More Dec 02, 2019 Astellas Enters into Definitive Agreement to Acquire Audentes Therapeutics Read More Oct 05, 2019 Audentes Therapeutics Presents New Positive Data from ASPIRO, the Clinical Trial Evaluating AT132 in Patients with X-Linked Myotubular Myopathy (XLMTM), at the 24th International Annual Congress of the World Muscle Society Read More May 01, 2019 Audentes Therapeutics Presents New Positive Data from ASPIRO, the Phase 1/2 Clinical Trial of AT132 for X-linked Myotubular Myopathy, at 22nd Annual Meeting of the American Society of Gene and Cell Therapy Read More Apr 23, 2019 Audentes Therapeutics Announces Launch of New State-of-the-Art Internal cGMP Plasmid Manufacturing Facility Read More Apr 08, 2019 Audentes Therapeutics Announces Expansion of AAV Technology Platform and Pipeline with New Development Programs for Duchenne Muscular Dystrophy and Myotonic Dystrophy Read More Pagination First page « First Previous page ‹ Previous Page 1 Page 2 Current page 3